Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors

Authors: Lorenza Vitale, Flavia Frabetti, Shane A Huntsman, Silvia Canaider, Raffaella Casadei, Luca Lenzi, Federica Facchin, Paolo Carinci, Maria Zannotti, Domenico Coppola, Pierluigi Strippoli

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

CYYR1 is a recently identified gene located on human chromosome 21 whose product has no similarity to any known protein and is of unknown function. Analysis of expressed sequence tags (ESTs) have revealed high human CYYR1 expression in cells belonging to the diffuse neuroendocrine system (DNES). These cells may be the origin of neuroendocrine (NE) tumors. The aim of this study was to conduct an initial analysis of sequence, splicing and expression of the CYYR1 mRNA in human NE tumors.

Methods

The CYYR1 mRNA coding sequence (CDS) was studied in 32 NE tumors by RT-PCR and sequence analysis. A subtle alternative splicing was identified generating two isoforms of CYYR1 mRNA differing in terms of the absence (CAG- isoform, the first described mRNA for CYYR1 locus) or the presence (CAG+ isoform) of a CAG codon. When present, this specific codon determines the presence of an alanine residue, at the exon 3/exon 4 junction of the CYYR1 mRNA. The two mRNA isoform amounts were determined by quantitative relative RT-PCR in 29 NE tumors, 2 non-neuroendocrine tumors and 10 normal tissues. A bioinformatic analysis was performed to search for the existence of the two CYYR1 isoforms in other species.

Results

The CYYR1 CDS did not show differences compared to the reference sequence in any of the samples, with the exception of an NE tumor arising in the neck region. Sequence analysis of this tumor identified a change in the CDS 333 position (T instead of C), leading to the amino acid mutation P111S. NE tumor samples showed no significant difference in either CYYR1 CAG- or CAG+ isoform expression compared to control tissues. CYYR1 CAG- isoform was significantly more expressed than CAG+ isoform in NE tumors as well as in control samples investigated. Bioinformatic analysis revealed that only the genomic sequence of Pan troglodytes CYYR1 is consistent with the possible existence of the two described mRNA isoforms.

Conclusion

A new "subtle" splicing isoform (CAG+) of CYYR1 mRNA, the sequence and the expression of this gene were defined in a large series of NE tumors.
Appendix
Available only for authorised users
Literature
1.
Vitale L, Casadei R, Canaider S, Lenzi L, Strippoli P, D'Addabbo P, Giannone S, Carinci P, Zannotti M: Cysteine and tyrosine-rich 1 (CYYR1), a novel unpredicted gene on human chromosome 21 (21q21.2), encodes a cysteine and tyrosine-rich protein and defines a new family of highly conserved vertebrate-specific genes. Gene. 2002, 290: 141-151. 10.1016/S0378-1119(02)00550-4.CrossRefPubMed
2.
Day R, Salzet M: The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches: redefining the diffuse neuroendocrine system. Neuroendocrinol Lett. 2002, 23: 447-451.PubMed
3.
Solcia E, Klöppel G, Sobin H: Histological typing of endocrine tumours. World Health Organization International Histological Classification of Tumours. 2000, Berlin: SpringerCrossRef
4.
Engels WR: Contributing software to the internet: the Amplify program. Trends Biochem Sci. 1993, 18: 448-450. 10.1016/0968-0004(93)90148-G.CrossRefPubMed
5.
Sharrocks AD: The design of primer for PCR. PCR Technology – Current Innovations. Edited by: Griffin HG, Griffin AM. 1994, CRC Press, Boca Raton, 5-11.
6.
Freeman WM, Walker SJ, Vrana KE: Quantitative RT-PCR: pitfalls and potential. Biotechniques. 1999, 26: 112-122. 124–125PubMed
7.
Davis LG, Kuehl WM, Battey JF: Basic Methods in Molecular Biology. 1994, Norwalk: Appleton & Lange
8.
Hiller M, Huse K, Szafranski K, Jahn N, Hampe J, Schreiber S, Backofen R, Platzer M: Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity. Nat Genet. 2004, 36: 1255-1257. 10.1038/ng1469. Erratum in: Nat Genet 2005, 37:106CrossRefPubMed
9.
10.
Sano T: The dispersed neuroendocrine system. Molecular and Cellular Endocrine Pathology. Edited by: Stefaneanu L, Sasano H, Kovacs K. 2000, London: Hodder Arnold, 353-373.
11.
Le Blanc I, Prevost MC, Dokhelar MC, Rosenberg AR: The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process. J Virol. 2002, 76: 10024-10029. 10.1128/JVI.76.19.10024-10029.2002.CrossRefPubMedPubMedCentral
12.
Pereboev AV, Ahmed N, thi Man N, Morris GE: Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain). Biochim Biophys Acta. 2001, 1527: 54-60.CrossRefPubMed
13.
Ilsley JL, Sudol M, Winder SJ: The WW domain: linking cell signalling to the membrane cytoskeleton. Cell Signal. 2002, 14 (3): 183-189. 10.1016/S0898-6568(01)00236-4.CrossRefPubMed
14.
Vitale L, Lenzi L, Huntsman SA, Canaider S, Frabetti F, Casadei R, Facchin F, Carinci P, Zannotti M, Coppola D, Strippoli P: Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors. Oncol Rep. 2006, 15: 1249-1256.PubMed
Metadata
Title
Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors
Authors
Lorenza Vitale
Flavia Frabetti
Shane A Huntsman
Silvia Canaider
Raffaella Casadei
Luca Lenzi
Federica Facchin
Paolo Carinci
Maria Zannotti
Domenico Coppola
Pierluigi Strippoli
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-66

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study

Research article

Lymphatic vessel density and function in experimental bladder cancer

Research article

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells

Research article

E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation

Research article

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

Research article

Prognostic factors associated with the survival of oral and pharyngeal carcinoma in Taiwan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits